Gilead develops solid tumour cell therapy with Gadeta
Gilead has option to buy biotech if things go well
X
Gilead develops solid tumour cell therapy with Gadeta
https://pharmaphorum.com/news/gilead-develops-solid-tumour-cell-therapy-with-gadeta/
Kite
Kite begins EU trial of CAR-T therapy
First patient has received axi-cel in Amsterdam hospital.
Kite keeps pressure on Novartis with CAR-T filing
Kite completes filing a day after rival Novartis.
Servier and Pfizer begin trials for off-the-shelf T-cell cancer therapy
Companies hope to challenge traiblazers Novartis and Kite.
Orphan drugs will fuel pharma’s future – and a pricing pushback too
Evaluate predicts sales could approach $8bn if approved.
Kite outlines vision for next gen cancer killing cells
Backed by Amgen, Kite outlines bold plan for developing CAR-T and TCR cells.
1 2